ONCY ONCOLYTICS BIOTECH INC

Nasdaq oncolyticsbiotech.com


$ 1.14 $ -0.05 (-4.24 %)    

Monday, 20-Oct-2025 15:59:56 EDT
QQQ $ 612.01 $ 7.61 (1.26 %)
DIA $ 467.44 $ 5.24 (1.13 %)
SPY $ 671.96 $ 6.91 (1.04 %)
TLT $ 91.60 $ 0.35 (0.38 %)
GLD $ 401.11 $ 14.16 (3.64 %)
$ 1.13
$ 1.16
$ 1.13 x 180
$ 1.21 x 1,500
$ 1.10 - $ 1.19
$ 0.33 - $ 1.51
1,297,339
na
94.42M
$ 1.07
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oncolytics-biotech-plans-move-from-canada-to-us-with-proposed-domestication-to-nevada

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company ...

 oncolytics-biotech-files-for-common-stock-offering-of-50m

- SEC Filing

 oncolytics-biotech-reports-pelareorep-boosts-survival-in-colorectal-cancer-patients

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company ...

 oncolytics-biotech-files-for-mixed-shelf-offering-of-up-to-150m

-SEC Filing

 lake-street-initiates-coverage-on-oncolytics-biotech-with-buy-rating-announces-price-target-of-7

Lake Street analyst Chad Messer initiates coverage on Oncolytics Biotech (NASDAQ:ONCY) with a Buy rating and announces Price...

 oncolytics-biotech-q2-eps-005-beats-010-estimate

Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(...

Core News & Articles

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherap...

 oncolytics-biotech-initiated-regulatory-discussions-with-fda-for-potential-registration-enabled-study-in-first-line-pancreatic-cancer

Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) support accele...

 oncolytics-biotech-presents-aggregated-translational-data-for-pelareorep

Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes af...

Core News & Articles

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, ...

Core News & Articles

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responsesNew analys...

 hc-wainwright--co-reiterates-buy-on-oncolytics-biotech-maintains-5-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION